Who is sponsoring NCT07084467?

NCT07084467 is sponsored by King's College London.

What drugs are being tested in NCT07084467?

Interventions in NCT07084467: EF1 guided CRT optimisation, Standard of Care (SOC).

What condition does NCT07084467 study?

NCT07084467 studies Cardiac Resynchronisation Therapy (CRT), Heart Failure.

Is NCT07084467 still recruiting?

NCT07084467 is currently not yet recruiting. Last updated 3 August 2025.

Last reviewed 2025-08-03 · How we verify

NCT07084467: EFFECT-CRT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study Testing a New Heart Scan Method to Improve Pacemaker Treatment for Heart Failure

Not yet recruiting NA Last updated 3 August 2025

What this trial tests

NA trial testing EF1 guided CRT optimisation in Cardiac Resynchronisation Therapy (CRT) in 400 participants. Not yet recruiting.

Timeline

1 August 2025

Primary endpoint
31 July 2030

31 July 2030

Quick facts

Lead sponsor	King's College London
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	400
Start date	1 August 2025
Primary completion	31 July 2030
Estimated completion	31 July 2030
Sites	1 location across United Kingdom

Drugs / interventions tested

EF1 guided CRT optimisation
Standard of Care (SOC) — full drug profile →

Conditions studied

Cardiac Resynchronisation Therapy (CRT) — all drugs for Cardiac Resynchronisation Therapy (CRT) →
Heart Failure — all drugs for Heart Failure →

Sponsor

King's College London

Who can join

18 and older, any sex, with Cardiac Resynchronisation Therapy (CRT) or Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cardiac resynchronization therapy (CRT) is a device treatment for patients with heart failure which cannot be managed by medications alone. CRT can help the heart contract more efficiently and improve the pumping function. However, many patients do not benefit from this treatment. Therefore, a better selection tool will help us to determine the most suitable patients to receive this treatment. A new measure of pumping function of the heart called: first-phase ejection fraction or EF1 has been shown a good tool to select suitable patients for CRT. EF1 is a sensitive measurement of heart function and can be easily measured by echocardiography (an ultrasound heart scan). The purpose of this study is to examine whether this new measurement (EF1) can predict outcomes and response to CRT treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cardiac Resynchronisation Therapy (CRT)

Currently open trials in the same condition.

NCT07254013 — Left Bundle Branch Area Pacing (LBBAP) Monitoring Assistant: Evaluation of Portable ECG Solution · NA · recruiting
NCT07469137 — THE RELATIONSHIP BETWEEN CARDIAC RESYNCHRONİZATION THERAPY RESPONSE IN HEART FAILURE PATIENTS AND YKL-40 LEVELS · active not recruiting

Other King's College London trials

Trials by the same sponsor.

NCT07357064 — Professional Decision Making in Childbirth. · not yet recruiting
NCT07341087 — Skin Inflammation in Perimenopause: A Probiotic Intervention Proof of Concept Trial · NA · recruiting
NCT07228962 — Cutaneous Biomarkers in Atopic Eczema Using a Non-Invasive Micro-Suction Device in Babies · not yet recruiting
NCT07365722 — Comparison of Two Non-surgical Procedure to Manage Gum Disease Around Implants. · NA · not yet recruiting
NCT07378488 — Dance/Movement Therapy for Functional Neurological Disorder · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07084467 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by King's College London
Last refreshed: 3 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07084467.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing